

## Special Issue

# The Path to Personalized Pain Management

### Message from the Guest Editors

The Path to Personalized Pain Management is evolving. New technology is expanding, ongoing, and changing established clinical surgical criteria, validated by meta-analysis and peer-reviewed publications, with eventual global acceptance. The intervertebral disc is the initial primary surgical source of pain in the cervical, thoracic, and lumbar spine, which can be readily confirmed with diagnostic and therapeutic injections. Soft tissue trauma will usually heal with time, but surgical pain care can speed up recovery. Successful surgical clinical outcomes can be personalized and achieved with the endoscopic visualization of pain generators, with patient verbal intraoperative feedback, on par with open or microsurgical decompression, but with less surgical morbidity. The future of personalized pain management is to focus on personal pain care and patient selection based on individual patient needs.

---

### Guest Editors

Dr. Kai-Uwe Lewandrowski

Dr. Anthony T Yeung


Dr. Xifeng Zhang

Dr. Ivo Abraham

---

### Deadline for manuscript submissions

closed (20 October 2023)



## Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 4.1  
Indexed in PubMed



[mdpi.com/si/142921](https://mdpi.com/si/142921)

*Journal of Personalized  
Medicine*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 4.1  
Indexed in PubMed



[mdpi.com/journal/  
jpm](https://mdpi.com/journal/jpm)



## About the Journal

### Message from the Editorial Board

*Journal of Personalized Medicine (JPM)*, ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

---

### Editors-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

---

### Author Benefits

#### High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

#### Journal Rank:

CiteScore - Q2 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).